NovaBay Pharmaceuticals, Inc.(NBY)Earnings, Financials & Key Ratios
NBY•AMEX
$1.88
$11M mkt cap·Price updated Apr 24, 2026
AboutNovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Show more
- Revenue$10M-6.4%
- EBITDA-$5M-45.7%
- Net Income-$7M+25.1%
- EPS (Diluted)-2.53+98.2%
- Gross Margin66.26%+13.9%
- EBITDA Margin-55.8%-55.7%
- Operating Margin-59.7%-52.2%
- Net Margin-73.85%+19.9%
- ROE-453.56%-226.2%
- ROIC-216.96%-258.1%
- Interest Coverage-6.46-166.7%
NBY Key Insights
NovaBay Pharmaceuticals, Inc. (NBY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 2.9x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NBY Price & Volume
NovaBay Pharmaceuticals, Inc. (NBY) stock price & volume — 10-year historical chart
Loading chart...
NBY Growth Metrics
NovaBay Pharmaceuticals, Inc. (NBY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.96%
5 Years8.19%
3 Years-1.4%
TTM-74.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM132.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM101.12%
Return on Capital
10 Years-198.76%
5 Years-96.22%
3 Years-118.55%
Last Year-218.85%
NBY Peer Comparison
NovaBay Pharmaceuticals, Inc. (NBY) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AYTU | 16.08M | 2.56 | -1.19 | 1.84% | -39.02% | -172.12% | 1.21 | |
 PRPH | 5.82M | 0.14 | -0.05 | -84.75% | -38.72% | -6.08% | 3.34 | |
 OGEN | 2.65M | 0.62 | -0.14 | -0.47% | 0.03 | |||
 CTXR | 12.04M | 0.67 | -0.20 | -48.28% | 0.02 | |||
 PCYO | 277.04M | 11.50 | 21.30 | -9.25% | 46.62% | 9.31% | 0.05 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 DERM | 106.45M | 5.21 | -7.24 | -29.11% | -15.49% | -45.4% | 1.28 | |
 CLX | 10.88B | 90.01 | 13.81 | 0.16% | 11.18% | 404.82% | 5.98 |
Compare NBY vs Peers
NovaBay Pharmaceuticals, Inc. (NBY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBY Income Statement
NovaBay Pharmaceuticals, Inc. (NBY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 11.9M | 18.23M | 12.51M | 6.6M | 9.93M | 10.2M | 14.4M | 10.46M | 9.78M | 2.83M |
| Revenue Growth % | 171.56% | 53.23% | -31.39% | -47.24% | 50.54% | 2.72% | 41.16% | -27.42% | -6.45% | -74.73% |
| Cost of Goods Sold | 2.46M | 2.78M | 1.5M | 1.74M | 3.97M | 3.69M | 6.62M | 4.37M | 3.3M | 1.29M |
| COGS % of Revenue | 20.71% | 15.27% | 12.02% | 26.34% | 39.96% | 36.15% | 45.98% | 41.81% | 33.74% | - |
| Gross Profit | 9.43M▲ 0% | 15.45M▲ 63.7% | 11.01M▼ 28.8% | 4.86M▼ 55.8% | 5.96M▲ 22.7% | 6.51M▲ 9.2% | 7.78M▲ 19.4% | 6.08M▼ 21.8% | 6.48M▲ 6.5% | 1.54M▲ 0% |
| Gross Margin % | 79.29% | 84.73% | 87.98% | 73.66% | 60.04% | 63.85% | 54.02% | 58.19% | 66.26% | 54.56% |
| Gross Profit Growth % | 202.34% | 63.74% | -28.75% | -55.83% | 22.69% | 9.24% | 19.43% | -21.81% | 6.53% | - |
| Operating Expenses | 20.41M | 22.76M | 18.88M | 14.26M | 12.39M | 15.38M | 22.2M | 10.19M | 12.32M | 9.27M |
| OpEx % of Revenue | 171.6% | 124.83% | 150.91% | 216.11% | 124.72% | 150.7% | 154.11% | 97.43% | 125.96% | - |
| Selling, General & Admin | 19.04M | 22.35M | 18.62M | 14.08M | 12.11M | 15.33M | 15.29M | 10.15M | 11.41M | 8.58M |
| SG&A % of Revenue | 160.07% | 122.58% | 148.84% | 213.32% | 121.85% | 150.26% | 106.13% | 97.1% | 116.69% | - |
| Research & Development | 1.37M | 410K | 259K | 184K | 285K | 44K | 174K | 34K | 42K | 10K |
| R&D % of Revenue | 11.52% | 2.25% | 2.07% | 2.79% | 2.87% | 0.43% | 1.21% | 0.33% | 0.43% | - |
| Other Operating Expenses | -68K | 12K | 19K | 0 | 0 | 0 | 6.74M | 0 | 865K | 676K |
| Operating Income | -10.98M▲ 0% | -7.31M▲ 33.4% | -7.87M▼ 7.7% | -9.4M▼ 19.4% | -6.43M▲ 31.6% | -8.86M▼ 37.9% | -14.42M▼ 62.7% | -4.1M▲ 71.5% | -5.84M▼ 42.3% | -7.73M▲ 0% |
| Operating Margin % | -92.31% | -40.1% | -62.93% | -142.45% | -64.69% | -86.85% | -100.09% | -39.23% | -59.7% | -273% |
| Operating Income Growth % | 47.74% | 33.43% | -7.66% | -19.43% | 31.64% | -37.91% | -62.68% | 71.55% | -42.35% | - |
| EBITDA | -10.87M | -7.22M | -7.61M | -9.34M | -6.38M | -8.74M | -13.93M | -3.75M | -5.46M | -7.54M |
| EBITDA Margin % | -91.35% | -39.58% | -60.8% | -141.46% | -64.17% | -85.68% | -96.74% | -35.83% | -55.8% | -266.29% |
| EBITDA Growth % | 47.88% | 33.6% | -5.39% | -22.75% | 31.71% | -37.15% | -59.37% | 73.12% | -45.7% | -74.85% |
| D&A (Non-Cash Add-back) | 114K | 95K | 266K | 65K | 51K | 119K | 483K | 356K | 381K | 190K |
| EBIT | -10.98M | -7.31M | -7.87M | -9.4M | -6.43M | -8.86M | -7.68M | -4.45M | -6.31M | -7.92M |
| Net Interest Income | 0 | 0 | 0 | -1.05M | 0 | 0 | 0 | -1.69M | -904K | -88K |
| Interest Income | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 1.05M | 0 | 0 | 0 | 1.69M | 904K | 88K |
| Other Income/Expense | -2.17M | -89K | 1.33M | -252K | -4.61M | 3.04M | 3.81M | -2.04M | -1.37M | -224K |
| Pretax Income | -13.15M▲ 0% | -7.4M▲ 43.7% | -6.54M▲ 11.6% | -9.65M▼ 47.6% | -11.03M▼ 14.3% | -5.82M▲ 47.2% | -10.61M▼ 82.1% | -6.14M▲ 42.1% | -7.21M▼ 17.3% | -7.95M▲ 0% |
| Pretax Margin % | -110.52% | -40.59% | -52.29% | -146.26% | -111.07% | -57.08% | -73.65% | -58.78% | -73.71% | -280.92% |
| Income Tax | 2K | 3K | 4K | 6K | 5K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.02% | -0.04% | -0.06% | -0.06% | -0.05% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -13.15M▲ 0% | -7.4M▲ 43.7% | -6.54M▲ 11.6% | -9.66M▼ 47.6% | -11.04M▼ 14.3% | -5.82M▲ 47.2% | -10.61M▼ 82.1% | -9.64M▲ 9.1% | -7.22M▲ 25.1% | 3.24M▲ 0% |
| Net Margin % | -110.54% | -40.61% | -52.33% | -146.36% | -111.12% | -57.08% | -73.65% | -92.2% | -73.85% | 114.59% |
| Net Income Growth % | 30.69% | 43.71% | 11.59% | -47.56% | -14.3% | 47.24% | -82.14% | 9.13% | 25.07% | 132.05% |
| Net Income (Continuing) | -13.15M | -7.4M | -6.54M | -9.66M | -11.04M | -5.82M | -10.61M | -6.14M | -7.21M | -7.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.5M | -13K | 1.19M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1047.97▲ 0% | -591.81▲ 43.5% | -564.17▲ 4.7% | -593.63▼ 5.2% | -385.53▲ 35.1% | -184.09▲ 52.3% | -353.59▼ 92.1% | -138.65▲ 60.8% | -2.53▲ 98.2% | 0.55▲ 0% |
| EPS Growth % | -50.87% | 43.53% | 4.67% | -5.22% | 35.06% | 52.25% | -92.07% | 60.79% | 98.18% | 101.12% |
| EPS (Basic) | -1058.69 | -591.81 | -473.83 | -593.63 | -385.53 | -184.09 | -353.59 | -139.14 | -2.53 | - |
| Diluted Shares Outstanding | 12.55K | 12.51K | 13.93K | 17.67K | 28.63K | 35.63K | 46K | 120K | 3.4M | 5.88M |
| Basic Shares Outstanding | 12.42K | 12.51K | 11.6K | 16.27K | 28.63K | 31.64K | 30K | 120K | 3.4M | 5.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NBY Balance Sheet
NovaBay Pharmaceuticals, Inc. (NBY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.47M | 8.99M | 8.61M | 9.38M | 14.24M | 13.17M | 11.33M | 7.15M | 1.94M | 2.9M |
| Cash & Short-Term Investments | 9.51M | 3.2M | 3.18M | 6.94M | 11.95M | 7.5M | 5.36M | 3.13M | 430K | 2.31M |
| Cash Only | 9.51M | 3.2M | 3.18M | 6.94M | 11.95M | 7.5M | 5.36M | 3.13M | 430K | 2.31M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.29M | 3.71M | 3.49M | 1.07M | 1.11M | 1.69M | 2.02M | 759K | 389K | 368K |
| Days Sales Outstanding | 70.1 | 74.38 | 101.93 | 58.96 | 40.64 | 60.31 | 51.09 | 26.5 | 14.52 | 31.7 |
| Inventory | 873K | 504K | 280K | 492K | 608K | 3.22M | 3.44M | 2.88M | 765K | 0 |
| Days Inventory Outstanding | 129.32 | 66.08 | 68 | 103.33 | 55.9 | 318.6 | 189.42 | 240.24 | 84.61 | 87.42 |
| Other Current Assets | 165K | 347K | 279K | 159K | 102K | 129K | 159K | 81K | 158K | 0 |
| Total Non-Current Assets | 910K | 1.08M | 753K | 1.84M | 996K | 10.81M | 5.07M | 1.88M | 1.49M | 589K |
| Property, Plant & Equipment | 371K | 471K | 201K | 1.36M | 520K | 604K | 1.95M | 1.38M | 1.01M | 195K |
| Fixed Asset Turnover | 32.07x | 38.70x | 62.23x | 4.85x | 19.10x | 16.89x | 7.39x | 7.56x | 9.70x | 6.04x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 4.53M | 348K | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 5.2M | 2.28M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 475K | 0 | 0 | 0 | 0 | 0 | 477K | 1.43M |
| Other Non-Current Assets | 539K | 613K | 77K | 477K | 476K | 476K | 489K | 497K | 3K | 42.88M |
| Total Assets | 15.38M▲ 0% | 10.08M▼ 34.5% | 9.36M▼ 7.1% | 11.22M▲ 19.9% | 15.24M▲ 35.8% | 23.98M▲ 57.4% | 16.4M▼ 31.6% | 9.03M▼ 44.9% | 3.42M▼ 62.1% | 3.49M▲ 0% |
| Asset Turnover | 0.77x | 1.81x | 1.34x | 0.59x | 0.65x | 0.43x | 0.88x | 1.16x | 2.86x | 0.48x |
| Asset Growth % | 202.95% | -34.47% | -7.12% | 19.86% | 35.81% | 57.36% | -31.61% | -44.91% | -62.11% | 88.19% |
| Total Current Liabilities | 4.32M | 4.98M | 3.85M | 5.69M | 2.83M | 3.44M | 4.26M | 4.28M | 2.84M | 1.45M |
| Accounts Payable | 455K | 466K | 551K | 331K | 302K | 1.04M | 1.08M | 1.13M | 623K | 76K |
| Days Payables Outstanding | 67.4 | 61.1 | 133.81 | 69.51 | 27.77 | 103.4 | 59.52 | 94.36 | 68.91 | 149.22 |
| Short-Term Debt | 0 | 0 | 0 | 2.61M | 0 | 105K | 0 | 1.14M | 565K | 149K |
| Deferred Revenue (Current) | 2.07M | 2.84M | 2.32M | 822K | 730K | 1.29M | 1.81M | 0 | 488K | 488K |
| Other Current Liabilities | 44K | 564K | 2.45M | 37K | 0 | 0 | 0 | 1.18M | 172K | 0 |
| Current Ratio | 3.35x | 1.81x | 2.24x | 1.65x | 5.03x | 3.83x | 2.66x | 1.67x | 0.68x | 0.68x |
| Quick Ratio | 3.15x | 1.71x | 2.16x | 1.56x | 4.81x | 2.89x | 1.85x | 1.00x | 0.41x | 0.41x |
| Cash Conversion Cycle | 132.02 | 79.36 | 36.12 | 92.77 | 68.77 | 275.51 | 180.98 | 172.38 | 30.22 | -30.11 |
| Total Non-Current Liabilities | 3.96M | 2.51M | 560K | 4.56M | 87K | 10.37M | 1.59M | 1.44M | 709K | 405K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 505K | 87K | 246K | 1.59M | 1.11M | 709K | 2.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.97M | 1.97M | 560K | 4.05M | 0 | 10.12M | 0 | 334K | 0 | 0 |
| Total Liabilities | 8.28M | 7.49M | 4.41M | 10.25M | 2.92M | 13.81M | 5.84M | 5.72M | 3.55M | 1.85M |
| Total Debt | 0 | 0 | 0 | 4.05M | 503K | 551K | 2.04M | 2.74M | 1.67M | 970K |
| Net Debt | -9.51M | -3.2M | -3.18M | -2.89M | -11.45M | -6.95M | -3.32M | -390K | 1.24M | -1.34M |
| Debt / Equity | - | - | - | 4.16x | 0.04x | 0.05x | 0.19x | 0.83x | - | 0.59x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.13x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.18x |
| Interest Coverage | - | - | - | -8.93x | - | - | - | -2.42x | -6.46x | -89.97x |
| Total Equity | 7.1M▲ 0% | 2.59M▼ 63.5% | 4.95M▲ 91.0% | 973K▼ 80.4% | 12.32M▲ 1166.0% | 10.17M▼ 17.4% | 10.55M▲ 3.8% | 3.31M▼ 68.6% | -129K▼ 103.9% | 1.63M▲ 0% |
| Equity Growth % | 239.29% | -63.47% | 90.98% | -80.36% | 1165.98% | -17.43% | 3.77% | -68.6% | -103.89% | 4490.91% |
| Book Value per Share | 565.86 | 207.37 | 355.76 | 55.08 | 430.20 | 285.47 | 229.43 | 27.62 | -0.04 | 0.28 |
| Total Shareholders' Equity | 7.1M | 2.59M | 4.95M | 973K | 12.32M | 10.17M | 10.55M | 3.31M | -129K | 1.63M |
| Common Stock | 153K | 154K | 171K | 279K | 418K | 478K | 20K | 112K | 49K | 60K |
| Retained Earnings | -103.67M | -111.07M | -114.98M | -125.02M | -136.06M | -141.89M | -158.15M | -174.85M | -183.46M | -183.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -149K | -243K | -509K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBY Cash Flow Statement
NovaBay Pharmaceuticals, Inc. (NBY) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.13M | -6.27M | -5.57M | -7.93M | -4.72M | -9.19M | -6.65M | -4.26M | -5.18M | -5.18M |
| Operating CF Margin % | -102% | -34.39% | -44.52% | -120.15% | -47.52% | -90.08% | -46.2% | -40.76% | -52.99% | - |
| Operating CF Growth % | 34.61% | 48.33% | 11.2% | -42.4% | 40.46% | -94.7% | 27.61% | 35.96% | -21.64% | -151.9% |
| Net Income | -13.15M | -7.4M | -6.54M | -9.66M | -11.04M | -5.82M | -10.61M | -6.14M | -7.21M | 3.24M |
| Depreciation & Amortization | 114K | 95K | 266K | 65K | 51K | 119K | 483K | 356K | 381K | 261K |
| Stock-Based Compensation | 1.75M | 2.04M | 594K | 621K | 701K | 1.15M | 220K | 0 | 0 | 4K |
| Deferred Taxes | 0 | 0 | 0 | -849K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.31M | 605K | -1.23M | 688K | 5.36M | -4.6M | 2.72M | 1.96M | 2.24M | 125K |
| Working Capital Changes | -3.16M | -1.6M | 1.35M | 1.2M | 210K | -38K | 533K | -433K | -595K | 548K |
| Change in Receivables | -1.58M | -1.51M | 774K | 2.32M | -317K | 452K | -305K | 846K | 291K | -53K |
| Change in Inventory | 472K | 369K | 198K | -212K | -116K | -243K | -217K | 162K | -272K | -355K |
| Change in Payables | -2.16M | -260K | 516K | -862K | 321K | -163K | 667K | -1.13M | -195K | 1.26M |
| Cash from Investing | -160K | -244K | -44K | -19K | -26K | -12.04M | -112K | -19K | 1.06M | 0 |
| Capital Expenditures | -160K | -244K | -44K | -19K | -26K | -52K | -112K | -19K | -6K | 0 |
| CapEx % of Revenue | 1.34% | 1.34% | 0.35% | 0.29% | 0.26% | 0.51% | 0.78% | 0.18% | 0.06% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -11.99M | 0 | 0 | 1.07M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 19.42M | 201K | 5.6M | 11.7M | 9.76M | 16.79M | 4.63M | 1.91M | 1.5M | -2.82M |
| Debt Issued (Net) | -1.66M | 0 | 0 | 2.35M | -2.56M | 105K | -105K | 1.53M | -1.49M | -7K |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 565K | 1000K | -1.17M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.82M |
| Share Repurchases | 0 | -48K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.99M |
| Other Financing | 7.43M | 201K | 12K | 58K | 7.11M | 0 | 1.7M | -181K | -115K | 3.38M |
| Net Change in Cash | 7.13M▲ 0% | -6.31M▼ 188.6% | -15K▲ 99.8% | 3.75M▲ 25126.7% | 5.01M▲ 33.6% | -4.45M▼ 188.7% | -2.13M▲ 52.0% | -2.44M▼ 14.3% | -2.49M▼ 2.3% | 1.58M▲ 0% |
| Free Cash Flow | -12.29M▲ 0% | -6.51M▲ 47.0% | -5.61M▲ 13.8% | -7.95M▼ 41.6% | -4.75M▲ 40.3% | -9.24M▼ 94.7% | -6.77M▲ 26.8% | -4.28M▲ 36.7% | -5.19M▼ 21.2% | -6.97M▲ 0% |
| FCF Margin % | -103.35% | -35.73% | -44.87% | -120.44% | -47.79% | -90.59% | -46.97% | -40.94% | -53.05% | -246.36% |
| FCF Growth % | 34.19% | 47.02% | 13.85% | -41.63% | 40.27% | -94.73% | 26.81% | 36.74% | -21.24% | -16.39% |
| FCF per Share | -979.76 | -520.75 | -403.02 | -449.90 | -165.79 | -259.45 | -147.09 | -35.67 | -1.53 | -1.53 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.85x | 0.85x | 0.82x | 0.43x | 1.58x | 0.63x | 0.44x | 0.72x | -2.15x |
| Interest Paid | 0 | 0 | 0 | 148K | 49K | 0 | 17K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 14K | 14K | 14K | 21K | 24K | 0 | 0 | 0 |
NBY Key Ratios
NovaBay Pharmaceuticals, Inc. (NBY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1313.13% | -152.72% | -173.42% | -325.9% | -166.11% | -51.79% | -102.37% | -139.03% | -453.56% | 198.47% |
| Return on Invested Capital (ROIC) | - | - | -1012.56% | - | -554.6% | -325.25% | -206.92% | -60.58% | -216.96% | -216.96% |
| Gross Margin | 79.29% | 84.73% | 87.98% | 73.66% | 60.04% | 63.85% | 54.02% | 58.19% | 66.26% | 54.56% |
| Net Margin | -110.54% | -40.61% | -52.33% | -146.36% | -111.12% | -57.08% | -73.65% | -92.2% | -73.85% | 114.59% |
| Debt / Equity | - | - | - | 4.16x | 0.04x | 0.05x | 0.19x | 0.83x | - | 0.59x |
| Interest Coverage | - | - | - | -8.93x | - | - | - | -2.42x | -6.46x | -89.97x |
| FCF Conversion | 0.92x | 0.85x | 0.85x | 0.82x | 0.43x | 1.58x | 0.63x | 0.44x | 0.72x | -2.15x |
| Revenue Growth | 171.56% | 53.23% | -31.39% | -47.24% | 50.54% | 2.72% | 41.16% | -27.42% | -6.45% | -74.73% |
NBY Frequently Asked Questions
NovaBay Pharmaceuticals, Inc. (NBY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NovaBay Pharmaceuticals, Inc. (NBY) reported $2.8M in revenue for fiscal year 2024.
NovaBay Pharmaceuticals, Inc. (NBY) saw revenue decline by 6.4% over the past year.
Yes, NovaBay Pharmaceuticals, Inc. (NBY) is profitable, generating $3.2M in net income for fiscal year 2024 (-73.8% net margin).
Dividend & Returns
NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -453.6%. Negative ROE indicates the company is unprofitable.
NovaBay Pharmaceuticals, Inc. (NBY) had negative free cash flow of $7.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More NBY
NovaBay Pharmaceuticals, Inc. (NBY) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates